Literature DB >> 14607085

Rheb fills a GAP between TSC and TOR.

Brendan D Manning1, Lewis C Cantley.   

Abstract

There has been much interest in determining the molecular and cellular functions of hamartin and tuberin, which are encoded by the genes TSC1 and TSC2 that are mutated in the tuberous sclerosis complex disease. Recently, several laboratories have independently reported a major breakthrough in this field. Together, these genetic, biochemical and cell-biological studies have demonstrated that the tuberin-hamartin complex inhibits target of rapamycin (TOR) signaling by acting as a GTPase-activating protein for the Ras-related small G protein Rheb.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607085     DOI: 10.1016/j.tibs.2003.09.003

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  172 in total

1.  RHEB/mTOR hyperactivity causes cortical malformations and epileptic seizures through increased axonal connectivity.

Authors:  Martina Proietti Onori; Linda M C Koene; Carmen B Schäfer; Mark Nellist; Marcel de Brito van Velze; Zhenyu Gao; Ype Elgersma; Geeske M van Woerden
Journal:  PLoS Biol       Date:  2021-05-26       Impact factor: 8.029

Review 2.  Staying alive: metabolic adaptations to quiescence.

Authors:  James R Valcourt; Johanna M S Lemons; Erin M Haley; Mina Kojima; Olukunle O Demuren; Hilary A Coller
Journal:  Cell Cycle       Date:  2012-05-01       Impact factor: 4.534

Review 3.  mTOR signaling in cancer cell motility and tumor metastasis.

Authors:  Hongyu Zhou; Shile Huang
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

4.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

5.  ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1).

Authors:  Audrey Carriere; Yves Romeo; Hugo A Acosta-Jaquez; Julie Moreau; Eric Bonneil; Pierre Thibault; Diane C Fingar; Philippe P Roux
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

6.  Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.

Authors:  Yu Gao; Ronald B Gartenhaus; Rena G Lapidus; Arif Hussain; Yanting Zhang; Xinghuan Wang; Han C Dan
Journal:  Mol Cancer Res       Date:  2015-09-15       Impact factor: 5.852

Review 7.  Programmed cell death and new discoveries in the genetics of parkinsonism.

Authors:  Robert E Burke
Journal:  J Neurochem       Date:  2007-12-10       Impact factor: 5.372

8.  Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development.

Authors:  Yann-Gaël Gangloff; Matthias Mueller; Stephen G Dann; Petr Svoboda; Melanie Sticker; Jean-Francois Spetz; Sung Hee Um; Eric J Brown; Silvia Cereghini; George Thomas; Sara C Kozma
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

Review 9.  Tumor metabolism: new opportunities for cancer therapy.

Authors:  Isabel Mérida; Antonia Avila-Flores
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

10.  Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).

Authors:  Mark Rolfe; Laura E McLeod; Phillip F Pratt; Christopher G Proud
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.